Tuesday, 29 November 2016

OncoTherics wins Innovate UK Global Feasibility Study Award

OncoTherics wins Innovate UK Global Feasibility Study Award. Project Title: Exploiting Tumour Hypoxia in Precision Medicine:  Advancing Novel Prodrug Therapies for Pancreatic Cancer with PMCC, a World-leading Canadian Cancer Centre.  As part of the award, OncoTherics will work with Alan Boyd Consultancy to explore a regulatory strategy for its novel hypoxia activated pro-drugs.
Posted by at No comments:

Tuesday, 1 November 2016

OCT1002 shows promising results in prostate cancer research

Researchers at Ulster University have just published the latest results of a three-year study looking at OCT1002 in combination with hormone therapy in prostate cancer.

The research programme was supported by Prostate Cancer UK through a £213,000 grant from the Movember Foundation and the latest results have been published in the Journal of Clinical Cancer Research
CLICK HERE to link to the paper.

CLICK HERE to hear Dr Declan McKenna speaking on ITV news about the exciting results.
Posted by at No comments:
Subscribe to: Posts (Atom)